Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, held at The St. Regis New York. The company aims to leverage its expertise in PLK1 inhibition to develop novel cancer therapies, particularly focusing on its lead asset, onvansertib, which targets treatment-resistant cancers. A pre-recorded fireside chat will be available on-demand starting July 11, 2022. For more details, visit Cardiff Oncology's website.
- None.
- None.
SAN DIEGO, July 5, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and one-on-one meetings at the William Blair Biotech Focus Conference 2022, which is taking place at The St. Regis New York on July 12 – 13, 2022.
The fireside chat will be pre-recorded and available on-demand beginning on Monday, July 11, 2022. A link to the recording will available on the "Events" section of the Cardiff Oncology website.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com.
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Amy Jobe, Ph.D
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-william-blair-biotech-focus-conference-2022-301580342.html
SOURCE Cardiff Oncology, Inc.
FAQ
What conference is Cardiff Oncology participating in on July 12-13, 2022?
What is the focus of Cardiff Oncology's therapies?
When will the fireside chat by Cardiff Oncology be available?
What is onvansertib?
Where can I find more information about Cardiff Oncology?
